Squarepoint’s Vaxcyte PCVX Stock Holding History

Squarepoint’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,900	Closed	-$1.47M	–	5208
2024 Q4	$1.47M	Buy	+17,900	New	+$1.78M	﹤0.01%	2704

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Squarepoint's PCVX Position: Q3 2025 in Review

Squarepoint sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 14,862 shares — an estimated $483K sold.

Squarepoint first reported a position in PCVX in Q4 2020 and held it in 11 quarters. The position peaked at $30.8M in Q4 2024. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

Squarepoint reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
Squarepoint sold 14,862 Vaxcyte shares in Q3 2025, an estimated $483K.
Squarepoint first reported a position in Vaxcyte in Q4 2020 and held it in 11 quarters.
Squarepoint's Vaxcyte position peaked at $30.8M in Q4 2024.
285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.